Go Pro
NYSE:RFL

Rafael Q3 2025 Earnings Report

Rafael logo
$1.93 -0.09 (-4.65%)
Closing price 09/24/2026 03:58 PM Eastern
Extended Trading
$1.91 -0.02 (-0.83%)
As of 07:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rafael EPS Results

Actual EPS
-$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
$0.36 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, June 11, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Rafael's Q4 2026 earnings is estimated for Wednesday, October 28, 2026, based on past reporting schedules

Rafael Earnings Headlines

Rafael Holdings Inc Share Price (RFL.US)
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) is a diversified holding company focused primarily on commercial real estate and life sciences. The company’s real estate activities include ownership and management of commercial properties, with a focus on properties in the New York metropolitan area and other strategic locations.

Through its life sciences investments and subsidiaries, Rafael Holdings has supported the development of oncology treatments and other pharmaceutical technologies. Its best-known biotechnology subsidiary, Rafael Pharmaceuticals, developed investigational cancer therapies, including devimistat, a treatment designed to target cancer-cell metabolism. These programs have been evaluated in clinical studies, although investigational products remain subject to regulatory approval and may not become commercially available.

Rafael Holdings was established following the separation of certain assets from IDT Corporation. The company is associated with entrepreneur Howard S. Jonas, who has played a significant leadership role in its development. Its operations and investments span commercial real estate and biotechnology, with activities primarily connected to the United States.

View Rafael Profile